Abstract

The key initiating process in atherogenesis is the subendothelial retention of apolipoprotein B-containing lipoproteins. Retained lipoproteins are chemically and enzymatically modified, inducing a chronic inflammatory response. Therapeutic approaches for atherosclerosis treatment have been focused on the control of risk factors, such as hypercholesterolemia, hypertension, and diabetes mellitus. Nonetheless, the efficacy of these strategies is limited and unfortunately the health problem persists. On the other hand, development of therapies targeting the interactions between low-density lipoproteins and components of the extracellular matrix has been poorly addressed. In this work, we review the response-to-retention hypothesis and the recent data on therapeutic approaches targeting the retentive process of proatherogenic low-density lipoproteins.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.